Get the Stockscreener App
66.41
1.11%
0.73
After Hours:
65.68
-0.73
-1.10%
Biomarin Pharmaceutical Inc stock is traded at $66.41, with a volume of 1.34M.
It is up +1.11% in the last 24 hours and down -1.41% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$65.68
Open:
$66.27
24h Volume:
1.34M
Relative Volume:
0.68
Market Cap:
$12.86B
Revenue:
$3.29B
Net Income/Loss:
$268.74M
P/E Ratio:
48.46
EPS:
1.3704
Net Cash Flow:
$759.12M
1W Performance:
-0.18%
1M Performance:
-1.41%
6M Performance:
+13.50%
1Y Performance:
+22.78%
1-Day Range:
$65.72
$66.88
1-Week Range:
$63.57
$66.88
52-Week Range:
$49.26
$70.98
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
66.41 | 12.71B | 3.29B | 268.74M | 759.12M | 1.3704 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Resumed | Morgan Stanley | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-20-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com
BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView
BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView
BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Biomarin stock rating at neutral By Investing.com - Investing.com South Africa
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Biomarin stock rating at neutral - Investing.com
BioMarin at Wells Fargo conference: growth, pipeline and integration - Investing.com India
BioMarin at Wells Fargo conference: growth, pipeline and integration By Investing.com - Investing.com Canada
BMRN: Strong growth, pipeline expansion, and global market execution drive future momentum - TradingView
(BMRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BioMarin Pharmaceutical Inc. Announces Positive Results Of Phase 3 VOXZOGO Study In Hypochondroplasia - marketscreener.com
BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence - Investing News Network
Ten healthcare stocks with A-rated valuations and strong revenue growth - TradingView
BioMarin pads case for Voxzogo expansion as achondroplasia competition field shifts - Fierce Pharma
A drug helped children with a rare growth disorder grow 2.33 cm more per year - Stock Titan
Don't Ignore The Insider Selling In BioMarin Pharmaceutical - simplywall.st
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Yahoo Finance
Royalty Deal Could Be A Big Development For BioMarin Stock (BMRN) - simplywall.st
Weekly Recap: TransCon CNP license and Alesta Therapeutics acquisition - TradingView
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: 37% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
BioMarin Pharmaceutical (BMRN), What Is Behind The Fresh Attention? - simplywall.st
BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It? - Yahoo Finance
EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock - Benzinga
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - Yahoo Finance
BioMarin (NASDAQ: BMRN) legal chief unloads 17,557 shares - Stock Titan
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset - Eastern Progress
Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A TargetUltragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
Officer at BioMarin (NASDAQ: BMRN) plans sale of 17,557 shares - Stock Titan
BioMarin to Participate in Upcoming Investor Conferences - Yahoo Finance
Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), BioMarin Pharmaceutical (BMRN) and Envista Holdings (NVST) - The Globe and Mail
CASI Pharmaceuticals (CASIF) sells Alesta stake to BioMarin, with possible future milestone payouts - Stock Titan
How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors - simplywall.st
Piper Sandler raises BioMarin stock price target on IP settlement By Investing.com - Investing.com South Africa
BioMarin To Get Royalties From Ascendis Under IP Settlement - Law360
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com
BioMarin announces global settlement with Ascendis - The Pharma Letter
BioMarin Completes Alesta Therapeutics Acquisition, Adding HPP Drug Candidate ALE1 - citybiz
BioMarin Announces Close of the Alesta Therapeutics Acquisition - Investing News Network
4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects - Eastern Progress
Piper Sandler raises BioMarin stock price target on IP settlement - investing.com
BioMarin completes acquisition of Alesta, making it a wholly owned subsidiary - TradingView
Canaccord reiterates BioMarin stock rating on Ascendis settlement By Investing.com - Investing.com Australia
Canaccord reiterates BioMarin stock rating on Ascendis settlement - Investing.com
BioMarin Secures Double-Digit Yuviwel Royalties In Settlement With Ascendis - insights.citeline.com
Ascendis Pharma (NASDAQ: ASND) strikes global YUVIWEL settlement with BioMarin - stocktitan.net
Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. Enter Binding Term Sheet for Global Settlement and License Agreement Related to Yuviwel and Navepegritide-Related Products - marketscreener.com
Morgan Stanley reiterates BioMarin stock rating on settlement value By Investing.com - Investing.com Nigeria
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
3.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):